Friday 6-20-2014 Progenics Pharmaceuticals Inc (PGNX) $PGNX opened at 4.34 hitting the high price of 4.41 and a day low of 4.23 with a total volume of 1,548,900. PGNX had a previous close of 4.33 and has been seeing an average volume of 1,749,445.
Overall Average: 56% Buy
Recent stock forum discussions about PGNX http://investorshangout.com/search?q=PGNX&...mp;yt0=Go!
Sales, Clinical Hold Removal, Trial Initiations, and Committee Recommendations - Analyst Notes on Geron, Zalicus, Northwest Biotherapeutics, Progenics and TG Therapeutics
PR Newswire - Tue Jun 17, 4:30AM CDT
Today, Analysts Review released its analysts' notes regarding Geron Corporation (NASDAQ: GERN), Zalicus Inc. (NASDAQ: ZLCS), Northwest Biotherapeutics, Inc. (NASDAQ: NWBO), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX) and TG Therapeutics, Inc. (NASDAQ: TGTX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3775-100free. (full story)
Today's Top Biotech Stocks to Watch: Achillion Pharmaceuticals, Nektar Therapeutics and Progenics Ph
George Budwell, The Motley Fool - Motley Fool - Fri Jun 13, 8:02AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Achillion Pharmaceuticals , Nektar Therapeutics and Progenics Pharmaceuticals . Achillion falling back down to Earth Shares of hepatitis C... (full story)
Progenics Pharmaceuticals, Inc. (PGNX) in Focus: Stock Rises 9.23% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 7:44AM CDT
Progenics Pharmaceuticals, Inc. (PGNX) was a big mover last session, as the company saw its shares rise over 9% on the day (full story)
Progenics Schedules Investor Conference Call Following FDA Advisory Committee
GlobeNewswire - Thu Jun 12, 2:40PM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq
GNX) chief executive officer Mark Baker will comment on the FDA Advisory Committee meeting held this week, in a conference call tomorrow, Friday, June 13, at 8:30 a.m. Eastern Time. (full story)
FDA Ad Comm Provides Recommendations Regarding the Potential Cardiovascular Risk Associated with the Class of Peripherally-active Opioid Receptor Antagonists and the Trials to Support Approval of Products for OIC
Business Wire - Thu Jun 12, 1:32PM CDT
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Progenics Pharmaceuticals (NASDAQ GNX) today reported that the Anesthetic and Analgesic Drug Products Advisory Committee of the Food and Drug Administration (FDA) has provided an assessment of potential cardiovascular risk associated with products in the class of peripherally-active opioid receptor antagonists (PAMORAS) and recommendations regarding the necessity, timing, design and size of cardiovascular outcomes trials to support approval of products in this class for the proposed indication of opioid-induced constipation (OIC) in patients taking opioids for chronic pain. (full story)
Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j7t8xn/neuro_endocrine) has announced the addition of the "Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Neuro Endocrine (Carcinoid) Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuro Endocrine (Carcinoid) Carcinoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Neuro Endocrine (Carcinoid) Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Neuro Endocrine (Carcinoid) Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Ipsen S.A. - Novartis AG - Progenics Pharmaceuticals, Inc. - Lexicon Pharmaceuticals, Inc. - Jiangsu Hengrui Medicine Co., Ltd. - Camurus AB - Vascular Biogenics Ltd. - Advanced Accelerator Applications - Foresee Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/j7..._endocrine (full story)
Progenics Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Consider and Provide Recommendations Regarding Peripherally-Acting Opioid Receptor Antagonists
GlobeNewswire - Wed Jun 11, 6:05AM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq GNX) today announced that NASDAQ has halted trading of the company's common stock. (full story)
Progenics Pharmaceuticals Up 10.7%, Shares Break Through Resistance (PGNX)
Comtex SmarTrend(R) - Mon Jun 09, 11:40AM CDT
Progenics Pharmaceuticals (NASDAQ GNX) is one of today's best performing low-priced stocks, up 10.7% to $3.83 on 1.2x average daily volume. Thus far today, Progenics Pharmaceuticals has traded 1.2 million shares, vs. average volume of 1.0 million shares per day. The stock has outperformed the Dow (10.7% to the Dow's 0.2%) and outperformed the S&P 500 (10.7% to the S&P's 0.2%) during today's trading. (full story)
Progenics Pharmaceuticals (PGNX) in Focus: Stock Falls 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 05, 7:49AM CDT
Progenics Pharmaceuticals, Inc. (PGNX) saw a big move last session,continuing the recent downtrend for PGNX, as the stock is now down nearly 6% in the past one-month time frame. (full story)
Technical Analysis on Biotech Equities -- Research on Incyte, Progenics Pharma, Immunomedics, and Arqule
PR Newswire - Thu Jun 05, 6:30AM CDT
The trading session on Wednesday, June 04, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,737.53, up 0.09% and the NASDAQ Composite closed at 4,251.64, up 0.41%. The S&P 500 finished the day 0.19% higher at 1,927.88. During the trading session, seven out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day 0.23% higher at 694.30, and the index has gained 3.81% in the previous one month. Investor-Edge has initiated coverage on the following equities: Incyte Corp. Ltd (NASDAQ: INCY), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Immunomedics Inc. (NASDAQ: IMMU) and Arqule Inc. (NASDAQ: ARQL). Free technical research on INCY, PGNX, IMMU and ARQL can be downloaded upon signing up at: (full story)
Progenics Pharmaceuticals CEO Mark Baker to Present at Jefferies Global Healthcare Conference
GlobeNewswire - Mon Jun 02, 1:30PM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq GNX), an oncology company focused on the development of innovative approaches to targeting and treating cancer, announced today that Chief Executive Officer Mark Baker will present on Thursday, June 5, at 10:00 AM EDT at the Jefferies Global Healthcare Conference in New York City. (full story)
Progenics Pharmaceuticals Down 5.7%, Shares Slide into the Red (PGNX)
Comtex SmarTrend(R) - Mon Jun 02, 10:10AM CDT
Progenics Pharmaceuticals (NASDAQ GNX) is one of today's worst performing low-priced stocks, down 5.7% to $3.83 on 1.4x average daily volume. Thus far today, Progenics Pharmaceuticals has traded 1.1 million shares, vs. average volume of 837,000 shares per day. The stock has underperformed the Dow (-5.7% to the Dow's -0.0%) and underperformed the S&P 500 (-5.7% to the S&P's -0.2%) during today's trading. (full story)
Progenics Pharmaceuticals' PSMA ADC Data Selected for Poster Highlight Presentation at ASCO 2014
GlobeNewswire - Fri May 30, 7:00AM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq GNX), an oncology company that is developing innovative approaches to targeting and treating prostate cancer, announced today that results from its phase 2 trial of PSMA ADC have been chosen to be included in the genitourinary (prostate) cancer poster highlights session at the annual meeting of the American Society of Clinical Oncology being held in Chicago, Illinois on May 30 - June 3. These data update previously presented results from a study of 83 patients with metastatic castrate-resistant prostate cancer who suffered from progressive disease despite treatment with at least one taxane-containing chemotherapy. (full story)
Traders Get Bullish on Shares of Progenics Pharmaceuticals, Shares Up 5.4% (PGNX)
Comtex SmarTrend(R) - Tue May 27, 12:44PM CDT
Progenics Pharmaceuticals (NASDAQ GNX) is one of today's best performing low-priced stocks, up 5.4% to $3.90 on 1.1x average daily volume. Progenics Pharmaceuticals has traded 968,000 shares thus far today, vs. average volume of 863,000 shares per day. The stock has outperformed the Dow (5.4% to the Dow's 0.3%) and outperformed the S&P 500 (5.4% to the S&P's 0.4%) during today's trading. (full story)
Progenics' Q1 Loss Narrows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 15, 10:10AM CDT
Progenics Pharmaceuticals, Inc.'s (PGNX) loss narrows in the first quarter of 2014. (full story)
Stocks Analysis on Top Gainers -- Research on Progenics Pharma, Lionbridge Technologies, Nuverra Environmental Solutions, and Senomyx
PR Newswire - Mon May 12, 10:30AM CDT
The US markets saw a positive sentiment on Friday, May 9, 2014, with the NASDAQ Composite closing at 4,071.87, up 0.50%, the Dow Jones Industrial Average ending the session 0.20% higher at 16,583.34, and the S&P 500 edging 0.15% higher to finish the trading session at 1,878.48. The session saw a positive impact from Consumer Discretionary, Health Care, and Consumer Staples along with a drag from Utilities, Energy, and Financials sectors. A number of stocks saw large movements, including Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Lionbridge Technologies Inc. (NASDAQ: LIOX), Nuverra Environmental Solutions Inc. (NYSE: NES) and Senomyx Inc. (NASDAQ: SNMX). Free technical research on PGNX, LIOX, NES and SNMX can be downloaded upon signing up at: (full story)
Metastatic Prostate Cancer - Pipeline Review, H1 2014: 9 Companies and 16 Drugs Profiled
M2 - Mon May 12, 6:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f52w3s/metastatic) has announced the addition of the "Metastatic Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Prostate Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Agonox - Camurus AB - Colby Pharmaceutical Company - Fountain Biopharma Inc. - MEI Pharma, Inc. - OXiGENE, Inc. - Progenics Pharmaceuticals, Inc. Drug Profiles: - cabazitaxel - pracinostat - leuprolide acetate - LU-901 - veliparib - Engineered Autologous T Cells [cyclophosphamide] - MEDI-6469 - CPC-410 - Actimab-P - Peptide to Inhibit MT1 MMP for Autoimmune Disorders, Inflammation and Oncology - MIP-1095 - FB-704A - Ceramide Analogs - KGP-94 - Vaccine For Oncolytic Newcastle Disease Virus - Glutathione Disulfide Liposomal For more information visit http://www.researchandmarkets.com/research/f52w3s/metastatic (full story)
Salix Q1 Earnings Boosted by Santarus Acquisition - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri May 09, 12:41PM CDT
Salix's (SLXP) first quarter 2014 earnings of 92 cents per share were far above the Zacks Consensus Estimate of 42 cents and the year-ago earnings of 53 cents per share. (full story)
Progenics Pharmaceuticals Announces First Quarter 2014 Financial Results
GlobeNewswire - Fri May 09, 6:31AM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq GNX) today announced its results of operations for the quarter ended March 31. (full story)
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/grpwf5/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Involved: - ATLAB Pharma SAS - AbbVie Inc. - Active Biotech AB - Astellas Pharma Inc. - AstraZeneca PLC - Bavarian Nordic A/S - Bellicum Pharmaceuticals, Inc. - Bind Therapeutics, Inc. - Bostwick Laboratories, Inc. - CellCentric Ltd. - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - Exelixis, Inc. - GTx, Inc. - GenSpera, Inc. - Genentech, Inc. - Medivation, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Novartis AG - Oncolytics Biotech Inc. - Oncothyreon Inc. - Onyx Pharmaceuticals, Inc. - Progenics Pharmaceuticals, Inc. - Sotio a.s. - Supratek Pharma Inc. - Synta Pharmaceuticals Corp. Drug Profiles: - enzalutamide - orteronel - custirsen sodium - tasquinimod - enzalutamide - cabozantinib (s)-malate - Prostvac - DCVAC/PCa - patupilone - DI-17-E-6 - olaratumab - navitoclax - vandetanib - PSMA ADC - GTx-758 - linsitinib - olaparib - panobinostat - carfilzomib - ganetespib - pelareorep - PX-866 - CV-9103 - G-202 - docetaxel targeted nanoparticles - buparlisib hydrochloride - NLG-8189 - Adenovirus/PSA Vaccine - TL-118 - CV-9104 For more information visit http://www.researchandmarkets.com/research/grpwf5/metastatic (full story)
Overall Average: 56% Buy
Recent stock forum discussions about PGNX http://investorshangout.com/search?q=PGNX&...mp;yt0=Go!
Sales, Clinical Hold Removal, Trial Initiations, and Committee Recommendations - Analyst Notes on Geron, Zalicus, Northwest Biotherapeutics, Progenics and TG Therapeutics
PR Newswire - Tue Jun 17, 4:30AM CDT
Today, Analysts Review released its analysts' notes regarding Geron Corporation (NASDAQ: GERN), Zalicus Inc. (NASDAQ: ZLCS), Northwest Biotherapeutics, Inc. (NASDAQ: NWBO), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX) and TG Therapeutics, Inc. (NASDAQ: TGTX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3775-100free. (full story)
Today's Top Biotech Stocks to Watch: Achillion Pharmaceuticals, Nektar Therapeutics and Progenics Ph
George Budwell, The Motley Fool - Motley Fool - Fri Jun 13, 8:02AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Achillion Pharmaceuticals , Nektar Therapeutics and Progenics Pharmaceuticals . Achillion falling back down to Earth Shares of hepatitis C... (full story)
Progenics Pharmaceuticals, Inc. (PGNX) in Focus: Stock Rises 9.23% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 7:44AM CDT
Progenics Pharmaceuticals, Inc. (PGNX) was a big mover last session, as the company saw its shares rise over 9% on the day (full story)
Progenics Schedules Investor Conference Call Following FDA Advisory Committee
GlobeNewswire - Thu Jun 12, 2:40PM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq
GNX) chief executive officer Mark Baker will comment on the FDA Advisory Committee meeting held this week, in a conference call tomorrow, Friday, June 13, at 8:30 a.m. Eastern Time. (full story) FDA Ad Comm Provides Recommendations Regarding the Potential Cardiovascular Risk Associated with the Class of Peripherally-active Opioid Receptor Antagonists and the Trials to Support Approval of Products for OIC
Business Wire - Thu Jun 12, 1:32PM CDT
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Progenics Pharmaceuticals (NASDAQ
GNX) today reported that the Anesthetic and Analgesic Drug Products Advisory Committee of the Food and Drug Administration (FDA) has provided an assessment of potential cardiovascular risk associated with products in the class of peripherally-active opioid receptor antagonists (PAMORAS) and recommendations regarding the necessity, timing, design and size of cardiovascular outcomes trials to support approval of products in this class for the proposed indication of opioid-induced constipation (OIC) in patients taking opioids for chronic pain. (full story) Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j7t8xn/neuro_endocrine) has announced the addition of the "Neuro Endocrine (Carcinoid) Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Neuro Endocrine (Carcinoid) Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuro Endocrine (Carcinoid) Carcinoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Neuro Endocrine (Carcinoid) Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Neuro Endocrine (Carcinoid) Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Ipsen S.A. - Novartis AG - Progenics Pharmaceuticals, Inc. - Lexicon Pharmaceuticals, Inc. - Jiangsu Hengrui Medicine Co., Ltd. - Camurus AB - Vascular Biogenics Ltd. - Advanced Accelerator Applications - Foresee Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/j7..._endocrine (full story)
Progenics Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Consider and Provide Recommendations Regarding Peripherally-Acting Opioid Receptor Antagonists
GlobeNewswire - Wed Jun 11, 6:05AM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq
GNX) today announced that NASDAQ has halted trading of the company's common stock. (full story) Progenics Pharmaceuticals Up 10.7%, Shares Break Through Resistance (PGNX)
Comtex SmarTrend(R) - Mon Jun 09, 11:40AM CDT
Progenics Pharmaceuticals (NASDAQ
GNX) is one of today's best performing low-priced stocks, up 10.7% to $3.83 on 1.2x average daily volume. Thus far today, Progenics Pharmaceuticals has traded 1.2 million shares, vs. average volume of 1.0 million shares per day. The stock has outperformed the Dow (10.7% to the Dow's 0.2%) and outperformed the S&P 500 (10.7% to the S&P's 0.2%) during today's trading. (full story) Progenics Pharmaceuticals (PGNX) in Focus: Stock Falls 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 05, 7:49AM CDT
Progenics Pharmaceuticals, Inc. (PGNX) saw a big move last session,continuing the recent downtrend for PGNX, as the stock is now down nearly 6% in the past one-month time frame. (full story)
Technical Analysis on Biotech Equities -- Research on Incyte, Progenics Pharma, Immunomedics, and Arqule
PR Newswire - Thu Jun 05, 6:30AM CDT
The trading session on Wednesday, June 04, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,737.53, up 0.09% and the NASDAQ Composite closed at 4,251.64, up 0.41%. The S&P 500 finished the day 0.19% higher at 1,927.88. During the trading session, seven out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day 0.23% higher at 694.30, and the index has gained 3.81% in the previous one month. Investor-Edge has initiated coverage on the following equities: Incyte Corp. Ltd (NASDAQ: INCY), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Immunomedics Inc. (NASDAQ: IMMU) and Arqule Inc. (NASDAQ: ARQL). Free technical research on INCY, PGNX, IMMU and ARQL can be downloaded upon signing up at: (full story)
Progenics Pharmaceuticals CEO Mark Baker to Present at Jefferies Global Healthcare Conference
GlobeNewswire - Mon Jun 02, 1:30PM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq
GNX), an oncology company focused on the development of innovative approaches to targeting and treating cancer, announced today that Chief Executive Officer Mark Baker will present on Thursday, June 5, at 10:00 AM EDT at the Jefferies Global Healthcare Conference in New York City. (full story) Progenics Pharmaceuticals Down 5.7%, Shares Slide into the Red (PGNX)
Comtex SmarTrend(R) - Mon Jun 02, 10:10AM CDT
Progenics Pharmaceuticals (NASDAQ
GNX) is one of today's worst performing low-priced stocks, down 5.7% to $3.83 on 1.4x average daily volume. Thus far today, Progenics Pharmaceuticals has traded 1.1 million shares, vs. average volume of 837,000 shares per day. The stock has underperformed the Dow (-5.7% to the Dow's -0.0%) and underperformed the S&P 500 (-5.7% to the S&P's -0.2%) during today's trading. (full story) Progenics Pharmaceuticals' PSMA ADC Data Selected for Poster Highlight Presentation at ASCO 2014
GlobeNewswire - Fri May 30, 7:00AM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq
GNX), an oncology company that is developing innovative approaches to targeting and treating prostate cancer, announced today that results from its phase 2 trial of PSMA ADC have been chosen to be included in the genitourinary (prostate) cancer poster highlights session at the annual meeting of the American Society of Clinical Oncology being held in Chicago, Illinois on May 30 - June 3. These data update previously presented results from a study of 83 patients with metastatic castrate-resistant prostate cancer who suffered from progressive disease despite treatment with at least one taxane-containing chemotherapy. (full story) Traders Get Bullish on Shares of Progenics Pharmaceuticals, Shares Up 5.4% (PGNX)
Comtex SmarTrend(R) - Tue May 27, 12:44PM CDT
Progenics Pharmaceuticals (NASDAQ
GNX) is one of today's best performing low-priced stocks, up 5.4% to $3.90 on 1.1x average daily volume. Progenics Pharmaceuticals has traded 968,000 shares thus far today, vs. average volume of 863,000 shares per day. The stock has outperformed the Dow (5.4% to the Dow's 0.3%) and outperformed the S&P 500 (5.4% to the S&P's 0.4%) during today's trading. (full story) Progenics' Q1 Loss Narrows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 15, 10:10AM CDT
Progenics Pharmaceuticals, Inc.'s (PGNX) loss narrows in the first quarter of 2014. (full story)
Stocks Analysis on Top Gainers -- Research on Progenics Pharma, Lionbridge Technologies, Nuverra Environmental Solutions, and Senomyx
PR Newswire - Mon May 12, 10:30AM CDT
The US markets saw a positive sentiment on Friday, May 9, 2014, with the NASDAQ Composite closing at 4,071.87, up 0.50%, the Dow Jones Industrial Average ending the session 0.20% higher at 16,583.34, and the S&P 500 edging 0.15% higher to finish the trading session at 1,878.48. The session saw a positive impact from Consumer Discretionary, Health Care, and Consumer Staples along with a drag from Utilities, Energy, and Financials sectors. A number of stocks saw large movements, including Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Lionbridge Technologies Inc. (NASDAQ: LIOX), Nuverra Environmental Solutions Inc. (NYSE: NES) and Senomyx Inc. (NASDAQ: SNMX). Free technical research on PGNX, LIOX, NES and SNMX can be downloaded upon signing up at: (full story)
Metastatic Prostate Cancer - Pipeline Review, H1 2014: 9 Companies and 16 Drugs Profiled
M2 - Mon May 12, 6:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f52w3s/metastatic) has announced the addition of the "Metastatic Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Prostate Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Agonox - Camurus AB - Colby Pharmaceutical Company - Fountain Biopharma Inc. - MEI Pharma, Inc. - OXiGENE, Inc. - Progenics Pharmaceuticals, Inc. Drug Profiles: - cabazitaxel - pracinostat - leuprolide acetate - LU-901 - veliparib - Engineered Autologous T Cells [cyclophosphamide] - MEDI-6469 - CPC-410 - Actimab-P - Peptide to Inhibit MT1 MMP for Autoimmune Disorders, Inflammation and Oncology - MIP-1095 - FB-704A - Ceramide Analogs - KGP-94 - Vaccine For Oncolytic Newcastle Disease Virus - Glutathione Disulfide Liposomal For more information visit http://www.researchandmarkets.com/research/f52w3s/metastatic (full story)
Salix Q1 Earnings Boosted by Santarus Acquisition - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri May 09, 12:41PM CDT
Salix's (SLXP) first quarter 2014 earnings of 92 cents per share were far above the Zacks Consensus Estimate of 42 cents and the year-ago earnings of 53 cents per share. (full story)
Progenics Pharmaceuticals Announces First Quarter 2014 Financial Results
GlobeNewswire - Fri May 09, 6:31AM CDT
Progenics Pharmaceuticals, Inc. (Nasdaq
GNX) today announced its results of operations for the quarter ended March 31. (full story) Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014: 33 Companies and 48 Drugs Profiled
M2 - Thu May 08, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/grpwf5/metastatic) has announced the addition of the "Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Companies Involved: - ATLAB Pharma SAS - AbbVie Inc. - Active Biotech AB - Astellas Pharma Inc. - AstraZeneca PLC - Bavarian Nordic A/S - Bellicum Pharmaceuticals, Inc. - Bind Therapeutics, Inc. - Bostwick Laboratories, Inc. - CellCentric Ltd. - CureVac GmbH - DexTech Medical AB - Eli Lilly and Company - Emergent BioSolutions Inc. - Exelixis, Inc. - GTx, Inc. - GenSpera, Inc. - Genentech, Inc. - Medivation, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - NewLink Genetics Corporation - Novartis AG - Oncolytics Biotech Inc. - Oncothyreon Inc. - Onyx Pharmaceuticals, Inc. - Progenics Pharmaceuticals, Inc. - Sotio a.s. - Supratek Pharma Inc. - Synta Pharmaceuticals Corp. Drug Profiles: - enzalutamide - orteronel - custirsen sodium - tasquinimod - enzalutamide - cabozantinib (s)-malate - Prostvac - DCVAC/PCa - patupilone - DI-17-E-6 - olaratumab - navitoclax - vandetanib - PSMA ADC - GTx-758 - linsitinib - olaparib - panobinostat - carfilzomib - ganetespib - pelareorep - PX-866 - CV-9103 - G-202 - docetaxel targeted nanoparticles - buparlisib hydrochloride - NLG-8189 - Adenovirus/PSA Vaccine - TL-118 - CV-9104 For more information visit http://www.researchandmarkets.com/research/grpwf5/metastatic (full story)
